Supplementary report of the Kelkar Committec

2933. DR. RATNAKAR PANDEY: SHRI RAJNI RANJAN SAHU:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1385 given in the Rajya Sabha on the 21st November, 1988 and state:

(a) when was the supplementary *report* submitted to Government by Kelkar Committee and whether the same has been examined- and

(b) by when the report will be placed on the Table of the House?

THE MINISTER OF INDUSTRY (SHRi J. VENGAL RAO): (a) and 0>) Kelkar Committee had submitted its supplementary report recently and the same is under examination.

Amount due on Streptomycin

2934. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstar red Question 3110 given in the Rajya Sabha on 7th December, 1987 and state:

(a) what is the position in respect to the difference between the pooled /com mon sale price and the retention price of Streptomycin payable by Synbiotics into the Drug Prices Equalisation Account;

(b) whether any calculation of the amount which is due has been carried out from 1979 and if so, what are the details of the total amount due;

(c) whether any notice has been served to the roirmanv for the recovery of the amount due and if not, by when the' notice would be served;

(d) whether his Ministry collected any amount on account of Streptomycin, and

(e) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) Information to the extent available, would be collected and laid on the Table of the House.

Under utilisation of IDPL capacities

2935. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what is the investment made and capacity established for each Ampicillin, 6APA, Erythromycin Doxycycline, Niacinamide and Griseofulvin by Indian Drugs & Pharmaceuticals Ltd.;

(b) what wa$_s$ the production of these drugs during the last three years and what is the installed capacity;

(c) what are the production fees and other payments made for each of these drugs to the foreign collaborators; and

(d) what are the reasons that these pro. jects are not being implemented and operated at dull rated capacity and what was the nime of the collaborator in each case?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (c) The information is given in the statement attached. *[See* Appendix CXVIII, Annexure No. 125].

(b) The present installed capacity and production during the last 3 years are as under:—

(UNIT M.T.)

Name *of* the Product	Present installed capacity	Production during		
		1985-86	1986-87	1987-88
Ampicillin 6-	35	1.5	2.5	5.7
APA	47	26.6*	1.9*	8.6*
Erythromycin	30	0.2		2.2